Impact of the COVID-19 pandemic on antimicrobial consumption and antimicrobial resistance

ABSTRACT

5PSQ-154 Table 1Antimicrobial COVID/pre-COVID (DDD/100D) Increase DDD/100D (%) Amoxicillin 60.23/2.19 +2650.98 Azithromycin 107.73/5.69 +1791.68 Cefotaxime 0.99/0.18 +461.22 Ceftriaxone 139.24/28.97 +380.67 Vancomycin 24.25/8.33 +199.40 Aztreonam 2.61/0.92 +185.49 Meropenem 43.29/24.39 +77.48 Cefuroxime 14.6/9.23 +60.77 Linezolid 27.57/17.19 +60.40 Cefixime 2.72/1.82 +49.32 Piperacillin/tazobactam 49.81/33.75 +47.58 Amoxicillin/clavulanate 95.23/79.96 +19.09 The most important changes in bacterial sensitivity are detailed in table 2. 5PSQ-154 Table 2Microorganism No. isolated January-December 2019 No. isolated January-June 2021 Antimicrobial Sensitivity January-December 2019 (%) Sensitivity January-June 2021 (%) Pearson’s Chi-square significance Escherichia coli 4085 1648 No change Klebsiella spp 1095 425 Gentamicin 93 86 p=0.000 Cefuroxime 78 73 p=0.036 Cefotaxime 81 76 p=0.028 Nitrofurantoin 87 81 p=0.010 Aztreonam 74 70 p=0.226 Ceftazidime 81 77 p=0.076 cefepime 82 78 p=0.069 Pseudomonas aeruginosa 507 195 Gentamicin 83 78 p=0.114 Staphylococcus aureus 878 400 No change Enterococcus faecalis 572 266 No change Enterococcus faecium 146 87 Nitrofurantoin 92 83 p=0.120 Ampicillin 12 6 p=0.305 Conclusion and relevanceImportant increase in hospital antimicrobial consumption was observed, especially for the beta-lactams and carbapenems.Minimal changes in antimicrobial susceptibility was observed, detected only in Klebsiella spp, Pseudomonas aeruginosa and Enterococcus faecium.Antimicrobial stewardship strategies can help to keep the consumption of antimicrobials within acceptable levels.References and/or acknowledgementsConflict of interestNo conflict of interest